[{"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-001", "question": "A 6-year-old boy with a history of Diamond-Blackfan anemia (DBA) treated with chronic corticosteroids and transfusions presents with progressive dyspnea and fatigue. Echocardiography reveals a restrictive cardiomyopathy with severe biventricular diastolic dysfunction and moderate pulmonary hypertension. Genetic testing confirms a pathogenic variant in RPS19. Which of the following is the most appropriate next step in management?", "options": ["Initiation of high-dose beta-blockers and ACE inhibitors", "Referral for combined heart-lung transplantation evaluation", "Immediate discontinuation of corticosteroids and transition to defibrotide", "Addition of L-leucine supplementation to current regimen", "Cardiac MRI with T1 mapping and extracellular volume quantification"], "answer": "D", "answer_index": 3, "explanation": "Diamond-Blackfan anemia is associated with ribosomal protein mutations, and L-leucine has been shown to improve ribosomal function and hematopoiesis in DBA. In patients with DBA-associated cardiomyopathy, addressing the underlying ribosomal dysfunction with leucine supplementation may improve cardiac function, whereas conventional heart failure therapies are less effective for this specific pathophysiology. Beta-blockers/ACE inhibitors would be insufficient, transplantation is premature without addressing the underlying metabolic defect, defibrotide is for hepatic veno-occlusive disease, and advanced imaging would not change management.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: M (secondary U). Verdict on keyed answer: Miskeyed / Not uniquely determinable. Key stem clues that drive (or fail to drive) a unique best answer: 6-year-old with DBA (RPS19 mutation), chronic corticosteroids/transfusions, progressive dyspnea/fatigue, echo revealing restrictive cardiomyopathy with severe biventricular diastolic dysfunction and moderate pulmonary hypertension; these suggest possible iron overload from transfusions but lack confirmatory details like ferritin or systolic function, failing to pinpoint a single etiology or management path. Main logical issue(s): Underspecified (U) due to missing iron studies, ejection fraction, or current therapies, leading to multiple defensible options (M) such as standard heart failure management (A), transplant referral for severe disease (B), or advanced imaging to assess fibrosis/iron (E); no internal contradictions, but prevents unique best answer. Main medical accuracy issue(s): Keyed D (L-leucine supplementation) is inaccurate as it's investigational for DBA anemia, not established for cardiomyopathy, which is typically transfusion-related iron overload rather than primary ribosomal dysfunction; rationale misrepresents pathophysiology and dismisses conventional therapies, contradicting mainstream guidelines (e.g., iron chelation priority in transfusion-dependent anemias). Minimal fix: Add to stem 'Serum ferritin is within normal limits, with no evidence of iron overload on liver MRI' and retain key D to isolate ribosomal etiology, making D unambiguously best.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (secondary U). Verdict on keyed answer: Miskeyed / Not uniquely determinable. Key stem clues that drive (or fail to drive) a unique best answer: 6-year-old with DBA (RPS19 mutation), chronic corticosteroids/transfusions, progressive dyspnea/fatigue, echo revealing restrictive cardiomyopathy with severe biventricular diastolic dysfunction and moderate pulmonary hypertension; these suggest possible iron overload from transfusions but lack confirmatory details like ferritin or systolic function, failing to pinpoint a single etiology or management path. Main logical issue(s): Underspecified (U) due to missing iron studies, ejection fraction, or current therapies, leading to multiple defensible options (M) such as standard heart failure management (A), transplant referral for severe disease (B), or advanced imaging to assess fibrosis/iron (E); no internal contradictions, but prevents unique best answer. Main medical accuracy issue(s): Keyed D (L-leucine supplementation) is inaccurate as it's investigational for DBA anemia, not established for cardiomyopathy, which is typically transfusion-related iron overload rather than primary ribosomal dysfunction; rationale misrepresents pathophysiology and dismisses conventional therapies, contradicting mainstream guidelines (e.g., iron chelation priority in transfusion-dependent anemias). Minimal fix: Add to stem 'Serum ferritin is within normal limits, with no evidence of iron overload on liver MRI' and retain key D to isolate ribosomal etiology, making D unambiguously best.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-002", "question": "A 34-year-old pregnant woman at 32 weeks gestation presents with acute-onset severe hypertension (200/120 mmHg), headache, and visual disturbances. Laboratory studies show thrombocytopenia (platelets 85,000/μL), elevated liver enzymes (AST 250 U/L, ALT 280 U/L), and creatinine 1.8 mg/dL. Magnesium sulfate is initiated. Despite aggressive antihypertensive therapy with labetalol and hydralazine, her blood pressure remains persistently elevated. Which of the following is the most appropriate next pharmacologic intervention?", "options": ["Immediate initiation of nitroprusside infusion", "Addition of oral nifedipine XL 30 mg daily", "Intravenous fenoldopam infusion titrated to effect", "Sublingual captopril 12.5 mg repeated every 30 minutes", "Intravenous esmolol bolus followed by continuous infusion"], "answer": "C", "answer_index": 2, "explanation": "Fenoldopam is a dopamine-1 receptor agonist that causes vasodilation without compromising uteroplacental blood flow and is safe in pregnancy for refractory hypertension. Nitroprusside is contraindicated due to risk of cyanide toxicity to the fetus. Nifedipine XL has slow onset and is inadequate for acute control. ACE inhibitors like captopril are contraindicated in pregnancy due to fetal renal toxicity. Esmolol may cause fetal bradycardia and is less ideal than fenoldopam for pregnancy-associated hypertensive emergencies.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: 34-year-old at 32 weeks gestation with acute severe hypertension (200/120 mmHg), headache, visual disturbances, thrombocytopenia (85,000/μL), elevated AST/ALT (250/280 U/L), creatinine 1.8 mg/dL, on magnesium sulfate; BP refractory to labetalol and hydralazine. These indicate severe preeclampsia/HELLP syndrome requiring safe acute antihypertensive in pregnancy. The question asks for the most appropriate next pharmacologic intervention for refractory hypertensive emergency. Fenoldopam (C) fits as a dopamine-1 agonist causing vasodilation without uteroplacental compromise, safe in pregnancy. Alternatives: A (nitroprusside) risks fetal cyanide toxicity; B (oral nifedipine XL) has slow onset, unsuitable for acute crisis; D (captopril) is an ACE inhibitor contraindicated due to fetal renal toxicity; E (esmolol) may cause fetal bradycardia, less ideal. No main logical issues; stem supports unique best answer without contradictions or underspecification. Main medical accuracy issues: None major; fenoldopam aligns with niche use in refractory pregnancy hypertension per case reports, though ACOG primarily recommends labetalol/hydralazine/nifedipine; rationale correctly notes contraindications. Minimal fix: Not needed, but adding 'after stabilizing for imminent delivery' to stem would enhance realism without changing answer.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: 34-year-old at 32 weeks gestation with acute severe hypertension (200/120 mmHg), headache, visual disturbances, thrombocytopenia (85,000/μL), elevated AST/ALT (250/280 U/L), creatinine 1.8 mg/dL, on magnesium sulfate; BP refractory to labetalol and hydralazine. These indicate severe preeclampsia/HELLP syndrome requiring safe acute antihypertensive in pregnancy. The question asks for the most appropriate next pharmacologic intervention for refractory hypertensive emergency. Fenoldopam (C) fits as a dopamine-1 agonist causing vasodilation without uteroplacental compromise, safe in pregnancy. Alternatives: A (nitroprusside) risks fetal cyanide toxicity; B (oral nifedipine XL) has slow onset, unsuitable for acute crisis; D (captopril) is an ACE inhibitor contraindicated due to fetal renal toxicity; E (esmolol) may cause fetal bradycardia, less ideal. No main logical issues; stem supports unique best answer without contradictions or underspecification. Main medical accuracy issues: None major; fenoldopam aligns with niche use in refractory pregnancy hypertension per case reports, though ACOG primarily recommends labetalol/hydralazine/nifedipine; rationale correctly notes contraindications. Minimal fix: Not needed, but adding 'after stabilizing for imminent delivery' to stem would enhance realism without changing answer.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-003", "question": "A 58-year-old man with metastatic renal cell carcinoma on nivolumab and ipilimumab combination therapy presents with acute respiratory failure requiring mechanical ventilation. Bronchoalveolar lavage shows lymphocytic predominance without infectious organisms. High-dose methylprednisolone (2 mg/kg/day) was initiated 72 hours ago without improvement. Which of the following is the most appropriate next step in management?", "options": ["Add infliximab 5 mg/kg single dose", "Initiate cyclophosphamide 1 g/m² IV", "Switch to dexamethasone 40 mg daily", "Begin plasma exchange therapy", "Add tocilizumab 8 mg/kg IV"], "answer": "A", "answer_index": 0, "explanation": "For steroid-refractory immune checkpoint inhibitor-related pneumonitis, TNF-alpha inhibition with infliximab is the recommended next-line therapy based on retrospective evidence showing improved outcomes. Cyclophosphamide is used for other immune-related adverse events like myocarditis but not first-line for pneumonitis. Switching corticosteroids is unlikely to help if already on high-dose methylprednisolone. Plasma exchange is not established for this condition. Tocilizumab (IL-6 inhibitor) is used for cytokine release syndrome but not specifically for checkpoint inhibitor pneumonitis.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 58-year-old with metastatic RCC on nivolumab-ipilimumab, acute respiratory failure on mechanical ventilation, BAL with lymphocytic predominance and no infection, no improvement after 72 hours of high-dose methylprednisolone (2 mg/kg/day). These point to severe, steroid-refractory immune checkpoint inhibitor (ICI)-related pneumonitis, where guidelines recommend adding infliximab as next-line therapy. Main logical issue(s), if any: None; the vignette provides sufficient details to discriminate options without contradictions or underspecification, supporting A as uniquely best. Main medical accuracy issue(s), if any: None; aligns with current ASCO/NCCN guidelines for managing grade 3-4 ICI pneumonitis refractory to corticosteroids, emphasizing TNF-alpha inhibition with infliximab based on retrospective data showing improved outcomes. Alternatives are appropriately inferior: B (cyclophosphamide) for myocarditis, not pneumonitis; C unlikely to add benefit over current steroids; D (plasma exchange) lacks evidence; E (tocilizumab) for cytokine release syndrome, not ICI pneumonitis. Minimal fix: No edit needed; item is already unambiguous and accurate. The clinical problem asks for the next management step in steroid-refractory ICI pneumonitis. Key findings include therapy context, respiratory failure, BAL results, and steroid non-response. Implied diagnosis: Immune-related adverse event. Keyed A fits without assumptions. (Word count: 218)\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 58-year-old with metastatic RCC on nivolumab-ipilimumab, acute respiratory failure on mechanical ventilation, BAL with lymphocytic predominance and no infection, no improvement after 72 hours of high-dose methylprednisolone (2 mg/kg/day). These point to severe, steroid-refractory immune checkpoint inhibitor (ICI)-related pneumonitis, where guidelines recommend adding infliximab as next-line therapy. Main logical issue(s), if any: None; the vignette provides sufficient details to discriminate options without contradictions or underspecification, supporting A as uniquely best. Main medical accuracy issue(s), if any: None; aligns with current ASCO/NCCN guidelines for managing grade 3-4 ICI pneumonitis refractory to corticosteroids, emphasizing TNF-alpha inhibition with infliximab based on retrospective data showing improved outcomes. Alternatives are appropriately inferior: B (cyclophosphamide) for myocarditis, not pneumonitis; C unlikely to add benefit over current steroids; D (plasma exchange) lacks evidence; E (tocilizumab) for cytokine release syndrome, not ICI pneumonitis. Minimal fix: No edit needed; item is already unambiguous and accurate. The clinical problem asks for the next management step in steroid-refractory ICI pneumonitis. Key findings include therapy context, respiratory failure, BAL results, and steroid non-response. Implied diagnosis: Immune-related adverse event. Keyed A fits without assumptions. (Word count: 218)", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-004", "question": "A 3-day-old term neonate presents with poor feeding, lethargy, and hypoglycemia (glucose 25 mg/dL). Physical exam reveals macroglossia, umbilical hernia, and mild hepatomegaly. Newborn screening shows elevated galactose and galactitol. Which of the following additional findings would be most specific for confirming the diagnosis?", "options": ["Elevated serum ammonia level", "Absent reducing substances in urine after lactose challenge", "Normal glycogen content on liver biopsy", "Deficient activity of galactose-1-phosphate uridyltransferase in erythrocytes", "Presence of cataract on ophthalmologic examination"], "answer": "C", "answer_index": 2, "explanation": "The presentation suggests galactosemia, but the key distinguishing feature is that in galactose epimerase deficiency (a rare form), liver biopsy shows normal glycogen content, whereas in classic galactosemia (GALT deficiency), glycogen is depleted. Elevated ammonia suggests urea cycle defect. Absent reducing substances would argue against galactosemia. GALT enzyme deficiency confirms classic galactosemia, not the epimerase variant. Cataracts occur in both forms and are not specific.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: K (miskeyed), secondary U (underspecified for subtype). Verdict on keyed answer: Miskeyed. Key stem clues that drive (or fail to drive) a unique best answer: Neonatal hypoglycemia, poor feeding, lethargy, hepatomegaly, elevated galactose/galactitol strongly suggest galactosemia; macroglossia and umbilical hernia are atypical for galactosemia, more characteristic of Beckwith-Wiedemann syndrome, but galactose elevation specifies galactosemia without uniquely pointing to epimerase deficiency. Main logical issue(s): Vignette supports D as unique best answer (standard confirmatory enzyme assay for classic galactosemia, the most likely diagnosis), but key is C; lacks critical detail (e.g., normal GALT activity) to justify epimerase over classic, making subtype underspecified. Main medical accuracy issue(s): Glycogen content on liver biopsy is not a recognized distinguisher between galactosemia types (both can have metabolic disruptions affecting glycogen); macroglossia/hernia not typical of galactosemia; rationale contains inaccuracies, as confirmation relies on specific enzyme assays, not biopsy; cataracts not specific to epimerase. Minimal fix: Revise key to D and remove rationale's inaccurate distinction; alternatively, add 'normal GALT activity' to stem to support epimerase and change C to deficient GALE activity.\",\n\"medical_accuracy_score\": 2,\n\"logical_validity\": false,\n\"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (miskeyed), secondary U (underspecified for subtype). Verdict on keyed answer: Miskeyed. Key stem clues that drive (or fail to drive) a unique best answer: Neonatal hypoglycemia, poor feeding, lethargy, hepatomegaly, elevated galactose/galactitol strongly suggest galactosemia; macroglossia and umbilical hernia are atypical for galactosemia, more characteristic of Beckwith-Wiedemann syndrome, but galactose elevation specifies galactosemia without uniquely pointing to epimerase deficiency. Main logical issue(s): Vignette supports D as unique best answer (standard confirmatory enzyme assay for classic galactosemia, the most likely diagnosis), but key is C; lacks critical detail (e.g., normal GALT activity) to justify epimerase over classic, making subtype underspecified. Main medical accuracy issue(s): Glycogen content on liver biopsy is not a recognized distinguisher between galactosemia types (both can have metabolic disruptions affecting glycogen); macroglossia/hernia not typical of galactosemia; rationale contains inaccuracies, as confirmation relies on specific enzyme assays, not biopsy; cataracts not specific to epimerase. Minimal fix: Revise key to D and remove rationale's inaccurate distinction; alternatively, add 'normal GALT activity' to stem to support epimerase and change C to deficient GALE activity.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-005", "question": "A 42-year-old woman with systemic lupus erythematosus and antiphospholipid syndrome on warfarin (INR 2.5-3.5) presents with acute right leg pain and swelling. Doppler ultrasound confirms extensive deep vein thrombosis despite therapeutic anticoagulation. Lupus anticoagulant is positive, and anti-β2-glycoprotein I antibodies are elevated. Which of the following management strategies is most appropriate?", "options": ["Switch to rivaroxaban 20 mg daily", "Increase warfarin target INR to 3.5-4.5", "Add hydroxychloroquine 400 mg daily to current regimen", "Initiate intravenous immunoglobulin 1 g/kg for two days", "Place an inferior vena cava filter"], "answer": "C", "answer_index": 2, "explanation": "In antiphospholipid syndrome with breakthrough thrombosis despite therapeutic warfarin, adding hydroxychloroquine has been shown to reduce thrombotic risk through multiple mechanisms including inhibition of platelet activation and neutralization of antiphospholipid antibodies. Direct oral anticoagulants like rivaroxaban are less effective in triple-positive APS. Higher INR targets increase bleeding risk without proven benefit. IVIG is reserved for catastrophic APS. IVC filters do not address the hypercoagulable state and increase long-term DVT risk.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include SLE and APS diagnosis, therapeutic warfarin (INR 2.5-3.5), breakthrough extensive DVT confirmed by Doppler, positive lupus anticoagulant, and elevated anti-β2-glycoprotein I antibodies, implying high-risk APS with venous thrombosis recurrence. These support adding hydroxychloroquine (HCQ) to reduce thrombotic risk via platelet inhibition and antibody neutralization, aligning with guidelines for APS management in SLE patients. Main logical issue(s): none; the stem provides sufficient details to discriminate options without contradictions or underspecification, allowing a single best choice. Main medical accuracy issue(s): none; the keyed answer reflects current mainstream standards (e.g., EULAR/APS guidelines recommending HCQ adjunctively in refractory APS/SLE), with accurate critiques of alternatives—DOACs like rivaroxaban inferior in high-risk APS per trials (e.g., TRAPS), higher INR unproven and risky, IVIG for catastrophic cases only, IVC filters not addressing hypercoagulability and increasing DVT risk. Minimal fix: none needed; item is unambiguous and accurate as written. The clinical problem asks for optimal management of breakthrough thrombosis in APS on anticoagulation; discriminating findings are therapeutic INR yet recurrent DVT with positive aPL markers; most likely next step is HCQ addition; keyed answer fits without assumptions; alternatives inferior due to inefficacy (A), bleeding risk (B), wrong indication (D), or failure to treat cause (E).\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include SLE and APS diagnosis, therapeutic warfarin (INR 2.5-3.5), breakthrough extensive DVT confirmed by Doppler, positive lupus anticoagulant, and elevated anti-β2-glycoprotein I antibodies, implying high-risk APS with venous thrombosis recurrence. These support adding hydroxychloroquine (HCQ) to reduce thrombotic risk via platelet inhibition and antibody neutralization, aligning with guidelines for APS management in SLE patients. Main logical issue(s): none; the stem provides sufficient details to discriminate options without contradictions or underspecification, allowing a single best choice. Main medical accuracy issue(s): none; the keyed answer reflects current mainstream standards (e.g., EULAR/APS guidelines recommending HCQ adjunctively in refractory APS/SLE), with accurate critiques of alternatives—DOACs like rivaroxaban inferior in high-risk APS per trials (e.g., TRAPS), higher INR unproven and risky, IVIG for catastrophic cases only, IVC filters not addressing hypercoagulability and increasing DVT risk. Minimal fix: none needed; item is unambiguous and accurate as written. The clinical problem asks for optimal management of breakthrough thrombosis in APS on anticoagulation; discriminating findings are therapeutic INR yet recurrent DVT with positive aPL markers; most likely next step is HCQ addition; keyed answer fits without assumptions; alternatives inferior due to inefficacy (A), bleeding risk (B), wrong indication (D), or failure to treat cause (E).", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-006", "question": "A 67-year-old man with ischemic cardiomyopathy (LVEF 25%) and cardiac resynchronization therapy defibrillator presents with recurrent appropriate shocks for ventricular tachycardia. He is on maximally tolerated doses of carvedilol, lisinopril, and spironolactone. Amiodarone was started but discontinued due to thyroid toxicity. Which of the following is the most appropriate next antiarrhythmic therapy?", "options": ["Mexiletine 200 mg three times daily", "Sotalol 80 mg twice daily", "Dofetilide 500 mcg twice daily with inpatient initiation", "Ranolazine 1000 mg twice daily", "Propafenone 150 mg three times daily"], "answer": "C", "answer_index": 2, "explanation": "Dofetilide is a class III antiarrhythmic that is effective for ventricular tachycardia in structural heart disease and does not have the non-cardiac toxicity profile of amiodarone. It requires inpatient initiation due to risk of torsades de pointes. Mexiletine has limited efficacy as monotherapy. Sotalol is contraindicated in severe systolic dysfunction. Ranolazine has antianginal but limited antiarrhythmic evidence for VT. Propafenone is contraindicated in structural heart disease due to proarrhythmic risk.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: 67-year-old with ischemic cardiomyopathy (LVEF 25%), CRT-D, recurrent VT shocks despite GDMT (carvedilol, lisinopril, spironolactone); amiodarone discontinued due to thyroid toxicity. These drive selection of an antiarrhythmic effective for VT in structural heart disease with low non-cardiac toxicity and suitable for heart failure. Main logical issues: None; stem provides sufficient details to discriminate a unique best answer without contradictions or underspecification. The question asks for the most appropriate next therapy, and options are comparable antiarrhythmics, allowing clear differentiation based on efficacy, safety in HF, and initiation requirements. Main medical accuracy issues: None; dofetilide aligns with AHA/ACC guidelines for VT in HF post-amiodarone, requiring inpatient initiation for TdP monitoring. Other options correctly eliminated: mexiletine limited as monotherapy; sotalol contraindicated in severe systolic dysfunction; ranolazine lacks strong VT evidence; propafenone proarrhythmic in structural disease. Item is clinically realistic and board-relevant. Minimal fix: None needed, as item is unambiguous and accurate. Best-answer defensibility: Clinical problem: Optimal antiarrhythmic for refractory VT in advanced HF. Discriminating findings: Low LVEF, structural disease, prior amiodarone toxicity. Implied: Class III agent safe in HF. Keyed (C) fits: Effective, monitored initiation. Alternatives worse: A limited efficacy; B HF contraindication; D insufficient VT data; E proarrhythmic risk.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: 67-year-old with ischemic cardiomyopathy (LVEF 25%), CRT-D, recurrent VT shocks despite GDMT (carvedilol, lisinopril, spironolactone); amiodarone discontinued due to thyroid toxicity. These drive selection of an antiarrhythmic effective for VT in structural heart disease with low non-cardiac toxicity and suitable for heart failure. Main logical issues: None; stem provides sufficient details to discriminate a unique best answer without contradictions or underspecification. The question asks for the most appropriate next therapy, and options are comparable antiarrhythmics, allowing clear differentiation based on efficacy, safety in HF, and initiation requirements. Main medical accuracy issues: None; dofetilide aligns with AHA/ACC guidelines for VT in HF post-amiodarone, requiring inpatient initiation for TdP monitoring. Other options correctly eliminated: mexiletine limited as monotherapy; sotalol contraindicated in severe systolic dysfunction; ranolazine lacks strong VT evidence; propafenone proarrhythmic in structural disease. Item is clinically realistic and board-relevant. Minimal fix: None needed, as item is unambiguous and accurate. Best-answer defensibility: Clinical problem: Optimal antiarrhythmic for refractory VT in advanced HF. Discriminating findings: Low LVEF, structural disease, prior amiodarone toxicity. Implied: Class III agent safe in HF. Keyed (C) fits: Effective, monitored initiation. Alternatives worse: A limited efficacy; B HF contraindication; D insufficient VT data; E proarrhythmic risk.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-007", "question": "A 28-year-old primigravida at 36 weeks gestation presents with progressive dyspnea and orthopnea. Echocardiography shows peripartum cardiomyopathy with LVEF 30%. After diuresis with furosemide, she remains symptomatic. Which of the following medications should be avoided until after delivery?", "options": ["Digoxin 0.125 mg daily", "Hydralazine 25 mg three times daily", "Isosorbide dinitrate 20 mg three times daily", "Sacubitril/valsartan 24/26 mg twice daily", "Metoprolol succinate 25 mg daily"], "answer": "D", "answer_index": 3, "explanation": "Sacubitril/valsartan contains an ARB (valsartan) which is contraindicated in pregnancy due to fetal renal toxicity and oligohydramnios risk, particularly in the third trimester. Digoxin, hydralazine, isosorbide dinitrate, and metoprolol are all acceptable in pregnancy for heart failure management. While ACE inhibitors and ARBs are absolutely contraindicated, the other medications listed can be used with appropriate monitoring.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the patient's 36-week gestation (third trimester pregnancy), diagnosis of peripartum cardiomyopathy with LVEF 30%, persistent symptoms post-diuresis, and the question focusing on medications to avoid until after delivery, implying pregnancy-specific contraindications. These clues point to avoiding agents with fetal toxicity risks, uniquely identifying sacubitril/valsartan (D) due to its ARB component causing renal toxicity and oligohydramnios. No main logical issues; the item is coherent, supports a single best answer without contradictions or underspecification, and the key matches it. No main medical accuracy issues; the rationale aligns with current guidelines (e.g., ACC/AHA heart failure management in pregnancy, FDA warnings on ARBs), where digoxin, hydralazine, isosorbide dinitrate, and metoprolol are acceptable with monitoring, while ARBs are contraindicated in the third trimester. The item's logic is precise and board-relevant, with no inaccuracies or outdated elements. Minimal fix: None needed, as the item is already unambiguous and accurate; however, for added clarity, the stem could explicitly state 'due to pregnancy contraindications' though it's not required.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the patient's 36-week gestation (third trimester pregnancy), diagnosis of peripartum cardiomyopathy with LVEF 30%, persistent symptoms post-diuresis, and the question focusing on medications to avoid until after delivery, implying pregnancy-specific contraindications. These clues point to avoiding agents with fetal toxicity risks, uniquely identifying sacubitril/valsartan (D) due to its ARB component causing renal toxicity and oligohydramnios. No main logical issues; the item is coherent, supports a single best answer without contradictions or underspecification, and the key matches it. No main medical accuracy issues; the rationale aligns with current guidelines (e.g., ACC/AHA heart failure management in pregnancy, FDA warnings on ARBs), where digoxin, hydralazine, isosorbide dinitrate, and metoprolol are acceptable with monitoring, while ARBs are contraindicated in the third trimester. The item's logic is precise and board-relevant, with no inaccuracies or outdated elements. Minimal fix: None needed, as the item is already unambiguous and accurate; however, for added clarity, the stem could explicitly state 'due to pregnancy contraindications' though it's not required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-008", "question": "A 5-year-old girl with history of recurrent sinopulmonary infections presents with new-onset ataxia and nystagmus. MRI brain shows diffuse cerebellar atrophy. Serum immunoglobulin levels reveal IgG 450 mg/dL, IgA 10 mg/dL, and IgM 15 mg/dL. Flow cytometry shows absent B cells. Which of the following genetic mutations is most likely responsible for this clinical presentation?", "options": ["BTK gene mutation", "CD40 ligand deficiency", "AICDA gene mutation", "RAG1 gene mutation", "ATM gene mutation"], "answer": "E", "answer_index": 4, "explanation": "Ataxia-telangiectasia (ATM gene mutation) presents with combined immunodeficiency (low immunoglobulins, absent B cells), recurrent infections, cerebellar ataxia, and oculomotor apraxia. BTK mutation causes X-linked agammaglobulinemia with absent B cells but no ataxia. CD40 ligand deficiency causes hyper-IgM syndrome with normal or increased IgM. AICDA mutation causes hyper-IgM syndrome type 2. RAG1 mutation causes severe combined immunodeficiency (SCID) but not typically with cerebellar atrophy.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: N (secondary: U). Verdict on keyed answer: No defensible answer. Key stem clues that drive (or fail to drive) a unique best answer: Recurrent sinopulmonary infections, new-onset ataxia and nystagmus, diffuse cerebellar atrophy on MRI, low IgG/IgA/IgM levels, and absent B cells on flow cytometry. These suggest a syndrome combining immunodeficiency and neurologic degeneration, but no option fully matches. Main logical issue(s): None of the options can be defended as responsible for the entire presentation; ATM (E) fits neurologic features and infections but not absent B cells, while BTK (A) fits absent B cells and immunodeficiency but not ataxia/cerebellar atrophy; others (B, C, D) mismatch immunoglobulin patterns or lack neurologic involvement. This makes the item unsolvable without a defensible best answer, potentially due to underspecification in aligning clues with real syndromes. Main medical accuracy issue(s): The keyed answer (E) and rationale inaccurately attribute absent B cells to ATM mutation (ataxia-telangiectasia), which typically features present but dysfunctional B cells, low IgA/IgE, variable IgG/IgM, and T-cell defects—not absent B cells, a hallmark of BTK (X-linked agammaglobulinemia). This misleads on pathophysiology and confuses with other immunodeficiencies. Minimal fix: Revise stem to change 'absent B cells' to 'decreased B cell numbers and function' to align with A-T and make E unambiguously correct.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"N\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N (secondary: U). Verdict on keyed answer: No defensible answer. Key stem clues that drive (or fail to drive) a unique best answer: Recurrent sinopulmonary infections, new-onset ataxia and nystagmus, diffuse cerebellar atrophy on MRI, low IgG/IgA/IgM levels, and absent B cells on flow cytometry. These suggest a syndrome combining immunodeficiency and neurologic degeneration, but no option fully matches. Main logical issue(s): None of the options can be defended as responsible for the entire presentation; ATM (E) fits neurologic features and infections but not absent B cells, while BTK (A) fits absent B cells and immunodeficiency but not ataxia/cerebellar atrophy; others (B, C, D) mismatch immunoglobulin patterns or lack neurologic involvement. This makes the item unsolvable without a defensible best answer, potentially due to underspecification in aligning clues with real syndromes. Main medical accuracy issue(s): The keyed answer (E) and rationale inaccurately attribute absent B cells to ATM mutation (ataxia-telangiectasia), which typically features present but dysfunctional B cells, low IgA/IgE, variable IgG/IgM, and T-cell defects—not absent B cells, a hallmark of BTK (X-linked agammaglobulinemia). This misleads on pathophysiology and confuses with other immunodeficiencies. Minimal fix: Revise stem to change 'absent B cells' to 'decreased B cell numbers and function' to align with A-T and make E unambiguously correct.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-009", "question": "A 55-year-old man with alcoholic cirrhosis presents with hepatic encephalopathy refractory to lactulose and rifaximin. He has recurrent episodes requiring hospitalization every 2-3 weeks. Transjugular intrahepatic portosystemic shunt (TIPS) is not an option due to severe pulmonary hypertension. Which of the following interventions has the strongest evidence for reducing recurrent hepatic encephalopathy in this patient?", "options": ["Daily polyethylene glycol 3350 17 g", "Empirical vancomycin 125 mg four times daily", "Oral L-ornithine L-aspartate 6 g three times daily", "Sodium benzoate 5 g twice daily", "Branch-chain amino acid supplementation three times daily"], "answer": "A", "answer_index": 0, "explanation": "Polyethylene glycol has been shown in randomized trials to be more effective than lactulose for acute hepatic encephalopathy and may reduce recurrence by more effectively clearing ammonia-producing bacteria from the gut. Vancomycin has similar efficacy to rifaximin but risk of resistance. L-ornithine L-aspartate has modest benefit as adjunct only. Sodium benzoate is second-line. Branch-chain amino acids improve nutrition but not specifically encephalopathy recurrence.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 55-year-old with alcoholic cirrhosis and HE refractory to lactulose/rifaximin, recurrent episodes every 2-3 weeks, TIPS contraindicated by severe pulmonary hypertension; question seeks intervention with strongest evidence for reducing recurrent HE. These clues point to need for alternative therapies beyond standard lactulose/rifaximin, emphasizing evidence strength. Main logical issue(s), if any: None; stem provides sufficient details for discrimination without contradictions or underspecification, allowing unique best answer (A) based on RCT evidence for PEG in refractory HE. Main medical accuracy issue(s), if any: Mostly accurate per emerging evidence (e.g., RCTs showing PEG superior to lactulose for acute HE resolution and potential recurrence reduction via gut clearance); however, AASLD guidelines prioritize rifaximin add-on, with PEG as alternative laxative—item aligns with board-level knowledge but lacks nuance on PEG's emerging role vs. established options like LOLA in some regions. Minimal fix: No fix needed, but to enhance precision, add 'based on randomized controlled trials' to stem for explicit evidence focus.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 55-year-old with alcoholic cirrhosis and HE refractory to lactulose/rifaximin, recurrent episodes every 2-3 weeks, TIPS contraindicated by severe pulmonary hypertension; question seeks intervention with strongest evidence for reducing recurrent HE. These clues point to need for alternative therapies beyond standard lactulose/rifaximin, emphasizing evidence strength. Main logical issue(s), if any: None; stem provides sufficient details for discrimination without contradictions or underspecification, allowing unique best answer (A) based on RCT evidence for PEG in refractory HE. Main medical accuracy issue(s), if any: Mostly accurate per emerging evidence (e.g., RCTs showing PEG superior to lactulose for acute HE resolution and potential recurrence reduction via gut clearance); however, AASLD guidelines prioritize rifaximin add-on, with PEG as alternative laxative—item aligns with board-level knowledge but lacks nuance on PEG's emerging role vs. established options like LOLA in some regions. Minimal fix: No fix needed, but to enhance precision, add 'based on randomized controlled trials' to stem for explicit evidence focus.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-010", "question": "A 34-year-old woman with metastatic HER2-positive breast cancer on trastuzumab, pertuzumab, and docetaxel presents with acute decompensated heart failure. Echocardiography shows global hypokinesis with LVEF 20%, markedly reduced from baseline 55%. Which of the following biomarkers would be most specific for differentiating trastuzumab-induced cardiomyopathy from anthracycline-like toxicity?", "options": ["Elevated serum troponin I with normal NT-proBNP", "Markedly elevated NT-proBNP with normal troponin", "Elevated soluble ST2 with normal galectin-3", "Increased urinary 8-hydroxy-2'-deoxyguanosine", "Elevated growth differentiation factor-15 (GDF-15)"], "answer": "A", "answer_index": 0, "explanation": "Trastuzumab-induced cardiotoxicity typically presents with elevated troponin (indicating myocyte injury) but relatively preserved NT-proBNP (less volume overload/stretch), reflecting its mechanism of reversible HER2 receptor blockade without direct cellular damage. Anthracycline toxicity shows both elevated troponin and markedly elevated NT-proBNP due to irreversible cellular damage. ST2 and galectin-3 are fibrosis markers not specific to this distinction. 8-OHdG is oxidative stress marker. GDF-15 is elevated in various cardiac conditions.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K. Verdict on keyed answer: Miskeyed. The clinical problem asks for the most specific biomarker pattern to distinguish trastuzumab-induced cardiomyopathy from anthracycline-like toxicity in a patient with acute decompensated HF and reduced LVEF on HER2-targeted therapy plus docetaxel. Key stem clues: metastatic HER2+ breast cancer on trastuzumab/pertuzumab/docetaxel, acute HF with LVEF drop from 55% to 20%, implying cardiotoxicity differentiation. Most likely: trastuzumab (type 2, reversible, no myocyte necrosis, typically normal troponin but elevated NT-proBNP in HF). Keyed answer A (elevated troponin/normal NT-proBNP) fits anthracycline (type 1) better but assumes unrealistic normal NT-proBNP in acute HF. Alternatives: B (elevated NT-proBNP/normal troponin) best fits trastuzumab by lacking troponin elevation; C (ST2/galectin-3) nonspecific fibrosis markers; D (8-OHdG) oxidative stress, not differentiating; E (GDF-15) nonspecific cardiac stress. Main logical issue: Unique best answer is B, but key is A, making it miskeyed. Main medical accuracy issues: Rationale incorrectly states trastuzumab causes troponin elevation without direct damage (contradicts type 2 mechanism: no necrosis, often normal troponin) and implies normal NT-proBNP in acute HF, which is inaccurate as stretch elevates it regardless. Item assumes anthracycline-like toxicity despite no anthracycline in regimen. Minimal fix: Change key to B and revise rationale to reflect standard type 1 vs type 2 cardiotoxicity biomarkers.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K. Verdict on keyed answer: Miskeyed. The clinical problem asks for the most specific biomarker pattern to distinguish trastuzumab-induced cardiomyopathy from anthracycline-like toxicity in a patient with acute decompensated HF and reduced LVEF on HER2-targeted therapy plus docetaxel. Key stem clues: metastatic HER2+ breast cancer on trastuzumab/pertuzumab/docetaxel, acute HF with LVEF drop from 55% to 20%, implying cardiotoxicity differentiation. Most likely: trastuzumab (type 2, reversible, no myocyte necrosis, typically normal troponin but elevated NT-proBNP in HF). Keyed answer A (elevated troponin/normal NT-proBNP) fits anthracycline (type 1) better but assumes unrealistic normal NT-proBNP in acute HF. Alternatives: B (elevated NT-proBNP/normal troponin) best fits trastuzumab by lacking troponin elevation; C (ST2/galectin-3) nonspecific fibrosis markers; D (8-OHdG) oxidative stress, not differentiating; E (GDF-15) nonspecific cardiac stress. Main logical issue: Unique best answer is B, but key is A, making it miskeyed. Main medical accuracy issues: Rationale incorrectly states trastuzumab causes troponin elevation without direct damage (contradicts type 2 mechanism: no necrosis, often normal troponin) and implies normal NT-proBNP in acute HF, which is inaccurate as stretch elevates it regardless. Item assumes anthracycline-like toxicity despite no anthracycline in regimen. Minimal fix: Change key to B and revise rationale to reflect standard type 1 vs type 2 cardiotoxicity biomarkers.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}]